EGEN, Inc. is developing gene-based biopharmaceuticals that rely on proprietary delivery technologies to create products that are safe, effective and well-characterized. Our versatile TheraPlas™ technology platform has proven to be an effective immunotherapy for treating various types of tumors when utilized in combination with an Interleukin-12 (IL-12) plasmid. While traditional chemotherapy regimens kill the fast-growing ovarian cancer cells, immunotherapy enhances the local and systemic immune response against the cancer cells, offering a more targeted and less toxic approach to cancer treatment. IL-12 is one of the most active cytokines for the induction of potent anti-cancer immunity acting through the induction T-lymphocyte and natural killer (NK) cell proliferation.
Pre-clinical studies have shown that EGEN-001 can inhibit tumors when administered either as a monotherapy and in combination with standard chemotherapy. In addition, clinical and pre-clincial studies have shown that EGEN-001 can be safely and repeatedly administered for the treatment of a variety of different cancers including ovarian, colorectal and brain. Clinical testing has shown that EGEN-001 can be repeatedly administered intraperitoneally with few side effects and may be useful in treating a variety of disseminated peritoneal malignancies.
